Compositions and methods for treating proliferative disorders
US-9447185-B2 · Sep 20, 2016 · US
Anti-KIR3D antibodies
US9828427B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9828427-B2 |
| Application number | US-201514924786-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 28, 2015 |
| Priority date | Jan 19, 2009 |
| Publication date | Nov 28, 2017 |
| Grant date | Nov 28, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.
First claim
Opening claim text (preview).
We claim: 1. A method of modulating T cell activity in a patient suffering from arthritis, rheumatoid arthritis, or spondylarthritis comprising the step of administering to said patient a composition comprising a pharmaceutically acceptable carrier or excipient and an antibody that specifically binds to an epitope within the KIR3DL2 domain 0 consisting of SEQ ID NO: 21, wherein said antibody inhibits proliferation of KIR3DL-expressing human T lymphocytes and comprises a constant region of human IgG isotype, wherein said antibody: (a) comprises an Fc region of an IgG isotype modified to decrease binding to Fc receptors; and/or (b) does not substantially induce ADCC of a KIR3DL-expressing target cell. 2. The method of claim 1 , further comprising administering to the patient an immune system suppressor. 3. The method of claim 1 , wherein said patient suffers from arthritis. 4. The method of claim 1 , wherein said patient suffers from rheumatoid arthritis. 5. The method of claim 1 , wherein said patient suffers from spondylarthritis. 6. The method of claim 1 , wherein said antibody does not substantially induce ADCC of a KIR3DL-expressing target cell. 7. The method of claim 1 , wherein said antibody comprises an Fc region of an IgG isotype modified to decrease binding to Fc receptors.
Assignees
Inventors
Classifications
Immunosuppressants, e.g. drugs for graft rejection · CPC title
specific for metastasis · CPC title
Immunomodulators · CPC title
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9828427B2 cover?
- The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.
- Who is the assignee on this patent?
- Innate Pharma
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2803. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).